On November 5, 2020 the medicinal product was officially included in the List of Prequalified Medicinal Products by the World Health Organization (WHO)
Prequalification of medicinal products is a procedure performed by the WHO to assess the quality, safety and efficacy of medicinal products.
The inclusion of the medicinal product in the List of Prequalified Medicinal Products opens up opportunities for Farmak to participate in procurements conducted by international procurement organizations for the needs of the planet population.
Dexamethasone phosphate, except for its main area of intended use, was also included in the list of medicinal products used in the treatment of complications caused by COVID-19.
During the prequalification, the Company underwent the process from the product pharmaceutical development and registration dossier formation to inspection of manufacturing sites by WHO experts.
